Please assess the completion status of the following clinical trial:

Trial Title: Adjuvant Post-radical Cystectomy Treatment for Bladder Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients not more than 70 years old.~* Radical cystectomy performed within 42 days with no microscopic or macroscopic residual after surgery (negative surgical safety margins)~* Having one or more of the risk factors ( P3b,P4a,G3 and /or positive LN)~* ECOG Performance Scale (0-2).~* Adequate liver functions.~* Adequate renal function serum (creatinine \< 1.5 mg).~* No evidence of distant metastasis or other malignancy.~Exclusion Criteria:~* patients who received radiotherapy or chemotherapy prior to radical cystectomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): post-operative radiotherapy will be done in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy Dose of Radiotherapy: 45 Gray Gy/30 fractions/3 weeks
- Arm 2 (Type: EXPERIMENTAL): adjuvant chemotherapy (gemcitabine and cisplatin) in addition to post operative radiotherapy in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy
- Arm 3 (Type: EXPERIMENTAL): Adjuvant chemotherapy alone in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy

Based on this trial design, predict the completion outcome and termination type (if applicable).